Z Gastroenterol 2011; 49(12): 1543-1548
DOI: 10.1055/s-0031-1281847
© Georg Thieme Verlag KG Stuttgart · New York

Review of the Literature and Description of a Case of Sclerosing Encapsulating Peritonitis Requiring Home Parenteral Nutrition

Durchsicht der Literatur und Fallbericht eines Patienten mit sklerosierender verkapselnder Peritonitis, der durch parenterale Ernährung zu Hause versorgt wird
K. C. Fragkos*
1   Centre for Gastroenterology & Nutrition, University College London
F. M. Al-Sulttan
2   Department of Histopathology, University College London Hospital
R. P. Mookerjee
3   Institute of Hepatology, University College London
A. Winstanley
2   Department of Histopathology, University College London Hospital
A. Forbes
2   Department of Histopathology, University College London Hospital
› Author Affiliations
Further Information

Publication History

15 August 2011

14 October 2011

Publication Date:
02 December 2011 (online)


We present a case of a 48 year old HIV patient, who had recurrent episodes of ascites since 2007. His history includes ischaemic heart disease, for which he was treated with atenolol from 2005 to 2007, and Type 2 diabetes; he was later started on propranolol 40 mg twice a day from 2007 for Didanosine-induced portal hypertension. Because of negative cultures and neutrophil count < 250 cells/μL, spontaneous bacterial peritonitis was excluded. However, some low grade-peritoneal irritation cannot be ruled out because his CRP varied from 24 to 258, during 2007 – 2009, without any other obvious inflammatory cause. He was finally diagnosed in July 2009 with sclerosing encapsulating peritonitis (SEP) based on clinical features of intestinal obstruction, histology and imaging, including computed tomography and magnetic resonance imaging. Propranolol was stopped in November 2009. Because of the patient’s severe intestinal obstruction, he was started on parenteral nutrition 2 L/day. Since then, his CRP has returned to normal levels and there is a great improvement of his clinical features. This case demonstrates beta-blockers as a potential cause of SEP, while the presence of some low-grade peritoneal inflammation leading to SEP is also very likely.


Wir präsentieren den Fall eines 48-jährigen HIV-positiven Patienten, der seit 2007 an periodisch auftretendem Aszites leidet. Seine Krankengeschichte beinhaltet zudem eine ischämische Herzerkrankung, die von 2005 – 2007 mit Atenolol behandelt wurde, und Typ-2-Diabetes; später im Jahr 2007 begann man aufgrund einer durch Didanosin herbeigeführten portalen Hypertension (durch Didanosin herbeigeführte Leberzirrhose) ihm 2-mal täglich 40 mg Propanolol zu verabreichen. Aufgrund negativer Blutkulturen und einer Neutrophilenzahl < 250 /μl wurde eine spontan bakterielle Peritonitis ausgeschlossen. Allerdings kann eine leichte peritoneale Irritation nicht ausgeschlossen werden, da sein CRP von 2007 – 2009 ohne jegliche andere offensichtliche Entzündungsursache zwischen 24 und 258 schwankte. Schließlich wurde bei ihm im Juli 2009 eine sklerosierende verkapselnde Peritonitis (SEP) diagnostiziert, basierend auf klinischen Merkmalen eines Darmverschlusses, Histologie und Bildgebung, einschließlich einer Computertomografie und einer Magnetresonanztomografie. Propanolol wurde im November 2009 abgesetzt. Aufgrund des schwerwiegenden Darmverschlusses wurde beim Patienten 2 l/Tag parenterale Ernährung angesetzt. Seitdem befindet sich sein CRP wieder auf normalem Niveau und seine klinischen Merkmale haben sich enorm verbessert. Dieser Fall zeigt, dass Betablocker eine potenzielle Ursache für SEP darstellen, jedoch gleichzeitig nicht ausgeschlossen werden kann, dass das Vorhandensein einer von leichten peritonealen Entzündungen zu einer SEP führt.

* This author’s name is also written as Constantinos C. Frangos.

  • References

  • 1 Minutolo V, Gagliano G, Angirillo G. et al. Intestinal obstruction due to idiopathic sclerosing encapsulating peritonitis. Clinical report and review of literature. G Chir 2008; 29: 173-176
  • 2 Cohen O, Abrahamson J, Ben-Ari J. et al. Sclerosing encapsulating peritonitis: Primary and Secondary Forms. J Clin Gastroenterol 1996; 22: 54-57
  • 3 Kalra S, Atia A, McKinney J. et al. Sclerosing encapsulating peritonitis associated with propranolol usage: a case report and review of the literature. J Dig Dis 2009; 10: 332-335
  • 4 Pusateri R, Ross R, Marshall R. et al. Sclerosing encapsulating peritonitis: report of a case with small bowel obstruction managed by long-term home parenteral hyperalimentation, and a review of the literature. Am J Kidney Dis 1986; 8: 56-60
  • 5 Koak Y, Gertner D, Forbes A. et al. Idiopathic sclerosing peritonitis. Eur J Gastroenterol Hepatol 2008; 20: 148-150
  • 6 Kawanishi H, Harada Y, Sakikubo E. et al. Surgical treatment for sclerosing encapsulating peritonitis. Adv Perit Dial 2000; 16: 252-256
  • 7 Ahlmén J, Burian P, Eriksson C. et al. Sclerosing encapsulating peritonitis once again. Perit Dial Int 1991; 11: 279-280
  • 8 Kawanishi H. Surgical treatment for encapsulating peritoneal sclerosis. Adv Perit Dial 2002; 18: 139-143
  • 9 Rajani R, Smyth J, Koffman CG. et al. Differential effect of sirolimus vs prednisolone in the treatment of sclerosing encapsulating peritonitis. Nephrol Dial Transplant 2002; 17: 2278-2280
  • 10 Owtschinnikow P. Peritonitis chronica fibrosa incapsulata. Arch Klin Chir 1907; 83: 623-634
  • 11 Bradley JA, McWhinnie DL, Hamilton DN. et al. Sclerosing obstructive peritonitis after continuous ambulatory peritoneal dialysis. Lancet 1983; 2: 113-114
  • 12 Hauglustaine D, van Meerbeek J, Monballyu J. et al. Sclerosing peritonitis with mural bowel fibrosis in a patient on long-term CAPD. Clin Nephrol 1984; 22: 158-162
  • 13 Lalloo S, Krishna D, Maharajh J. Abdominal cocoon associated with tuberculous pelvic inflammatory disease. Br J Radiol 2002; 75: 174-176
  • 14 Maguire D, Srinivasan P, O'Grady J. et al. Sclerosing encapsulating peritonitis after orthotopic liver transplantation. Am J Surg 2001; 182: 151-154
  • 15 Sigaroudinia MO, Baillie C, Ahmed S. et al. Sclerosing encapsulating peritonitis – a rare complication of ventriculoperitoneal shunts. J Pediatr Surg 2008 43.
  • 16 Sillero JM, Calvet X, Musulen E. et al. Idiopathic pylephlebitis and idiopathic sclerosing peritonitis in a man with protein S deficiency. J Clin Gastroenterol 2001; 32: 262-265
  • 17 Brown P, Baddeley H, Read AE. et al. Sclerosing peritonitis, an unusual reaction to a β-adrenergic-blocking drug (practolol). Lancet 1974; 2: 1477-1481
  • 18 Dobbie JW. Pathogenesis of peritoneal fibrosing syndromes (sclerosing peritonitis) in peritoneal dialysis. Perit Dial Int 1992; 12: 14-27
  • 19 Kawanishi H. Encapsulating peritoneal sclerosis. Nephrology (Carlton) 2005; 10: 249-255
  • 20 Eltringham WK, Espiner HJ, Windsor CWO. et al. Sclerosing peritonitis due to practolol: A report on 9 cases and their surgical management. Br J Surg 1977; 64: 229-235
  • 21 Sieck JO, Cowgill R, Larkworthy W. Peritoneal encapsulation and abdominal cocoon. Case reports and a review of the literature. Gastroenterology 1983; 84: 1597-1601
  • 22 Masuda C, Fujii Y, Kamiya T. et al. Idiopathic sclerosing peritonitis in a man. Intern Med 1993; 32: 552-555
  • 23 Burstein M, Galun E, Ben-Chetrit E. Idiopathic sclerosing peritonitis in a man. J Clin Gastroenterol 1990; 12: 698-701
  • 24 Xu P, Chen LH, Li YM. Idiopathic sclerosing encapsulating peritonitis (or abdominal cocoon): a report of 5 cases. World J Gastroenterol 2007; 13: 3649-3651
  • 25 George C, Al-Zwae K, Nair S. et al. Computed tomography appearances of sclerosing encapsulating peritonitis. Clin Radiol 2007; 62: 732-737
  • 26 Mesquita M, Guillaume MP, Dratwa M. First use of tamoxifen in an HIV patient with encapsulating peritoneal sclerosis. Clin Drug investig 2007; 27: 727-729
  • 27 Rivera M, Martins J, Tenorio MT. et al. Quiz page. A peritoneal dialysis patient with HIV infection and abdominal pain: massive sclerosing encapsulating peritonitis. Am J Kidney Dis 2007; 50: A51-52
  • 28 Johnson DW, Cho Y, Livingston BE. et al. Encapsulating peritoneal sclerosis: incidence, predictors, and outcomes. Kidney Int 2010; 77: 904-912
  • 29 Nakayama M, Yamamoto H, Ikeda M. et al. Risk factors and preventive measures for encapsulating peritoneal sclerosis – Jikei experience 2002. Adv Perit Dial 2002; 18: 144-148
  • 30 Evans LT, Kim WR, Poterucha JJ. et al. Spontaneous bacterial peritonitis in asymptomatic outpatients with cirrhotic ascites. Hepatology 2003; 37: 897-901
  • 31 Runyon BA, Hoefs JC. Culture-negative neutrocytic ascites: a variant of spontaneous bacterial peritonitis. Hepatology 1984; 4: 1209-1211
  • 32 Leport J, Devars Du Mayne JF, Hay JM. et al. Chylous ascites and encapsulating peritonitis: unusual complications of spontaneous bacterial peritonitis. Am J Gastroenterol 1987; 82: 463-466
  • 33 Wong CL, Holroyd-Leduc J, Thorpe KE. et al. Does this patient have bacterial peritonitis or portal hypertension? How do I perform a paracentesis and analyze the results?. JAMA 2008; 299: 1166-1178
  • 34 Kim MY, Koo JH, Yeon JW. et al. Ileal obstruction caused by idiopathic sclerosing encapsulating peritonitis. Abdom Imaging 1999; 24: 82-84
  • 35 Okamoto N, Maeda K, Fujisaki M. et al. Abdominal cocoon in an aged man: report of a case. Surg Today 2007; 37: 258-260
  • 36 Gupta S, Shirahatti RG, Anand J. CT findings of an abdominal cocoon. AJR Am J Roentgenol 2004; 183: 1658-1660
  • 37 Stanley MM, Reyes CV, Greenlee HB. et al. Peritoneal fibrosis in cirrhotics treated with peritoneovenous shunting for ascites. An autopsy study with clinical correlations. Dig Dis Sci 1996; 41: 571-577
  • 38 Lo WK, Kawanishi H. Encapsulating peritoneal sclerosis – medical and surgical treatment. Perit Dial Int 2009; 29 (Suppl. 02) 211-214